# Comparison of Low and Intermediate Dose Low-molecular-weight Heparin to Prevent Recurrent Venous Thromboembolism in Pregnancy

Study · id `cardio:ct-nct01828697` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01828697](<https://clinicaltrials.gov/study/NCT01828697>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT01828697

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1110 participants.

## Technical summary

Registry record NCT01828697. Randomized; no masking; primary purpose prevention. Start 2013-04-24 (actual); primary completion 2021-10-31 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 1110 participants (enrolled count; ClinicalTrials.gov record NCT01828697, source copy `cardio:ctgov-nct01828697-2022-05-26`, retrieved 2026-10-31)
- Started: 2013-04-24 (actual) (ClinicalTrials.gov record NCT01828697, source copy `cardio:ctgov-nct01828697-2022-05-26`, retrieved 2026-10-31)
- Primary completion: 2021-10-31 (actual) (ClinicalTrials.gov record NCT01828697, source copy `cardio:ctgov-nct01828697-2022-05-26`, retrieved 2026-10-31)
- Completion: 2021-10-31 (actual) (ClinicalTrials.gov record NCT01828697, source copy `cardio:ctgov-nct01828697-2022-05-26`, retrieved 2026-10-31)
- Countries: United States; Belgium; Canada; Denmark; France; Ireland; Netherlands; Norway; Russia; Spain (ClinicalTrials.gov record NCT01828697, source copy `cardio:ctgov-nct01828697-2022-05-26`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01828697-2022-05-26`, retrieved 2026-10-31)

## The registry's words

- Brief title: Comparison of Low and Intermediate Dose Low-molecular-weight Heparin to Prevent Recurrent Venous Thromboembolism in Pregnancy
- Acronym: Highlow
- Condition: Deep Venous Thrombosis
- Condition: Pulmonary Embolism
- Intervention (Drug): Low dose nadroparin
- Intervention (Drug): Intermediate dose nadroparin
- Intervention (Drug): Low dose enoxaparin
- Intervention (Drug): Intermediate dose enoxaparin
- Intervention (Drug): Low dose dalteparin
- Intervention (Drug): Intermediate dose dalteparin
- Intervention (Drug): Fixed low dose tinzaparin
- Intervention (Drug): Intermediate dose tinzaparin
- Lead sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Lead sponsor class: OTHER
- Collaborator: Netherlands Organisation for Scientific Research
- Collaborator class: OTHER\_GOV
- Collaborator: Aspen Pharma
- Collaborator class: UNKNOWN
- Collaborator: CHU of Saint Etienne: French Ministry of Health Grant (sponsor of the French part of the study)
- Collaborator class: UNKNOWN
- Collaborator: Rotunda Hospital: Definitive Interventions and Feasibility Awards (DIFA) 2017 (sponsor of the Irish part of the study))
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Deep vein thrombosis (`cardio:deep-vein-thrombosis`)
- Registry condition terms include this condition: Pulmonary embolism (`cardio:pulmonary-embolism`)
- Registry lists this organization as the lead sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (`cardio:org-academisch-medisch-centrum-universiteit-van-amsterdam-amc-662d32`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Intermediate-dose versus low-dose low-molecular-weight heparin in pregnant and post-partum women with a history of venous thromboembolism (Highlow study): an open-label, multicentre, randomised, controlled trial (`cardio:pubmed-36354038`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Onset of labor and use of analgesia in women using thromboprophylaxis with 2 doses of low-molecular-weight heparin: insights from the Highlow study (`cardio:pubmed-36695396`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: e569221cf7b4cd0aa3045a675f4aec8592dee8d0ecb7e6c67812302b94b49094
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
